Cargando…

Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide

INTRODUCTION: We aimed to investigate whether treatment with exenatide could increase time in range (TIR) and decrease glycemic variability, and to evaluate the association between TIR and endothelial injury in patients with type 2 diabetes mellitus (T2DM). METHODS: Two-hundred patients with T2DM tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le, Yunyi, Yang, Kun, Yang, Jin, Fu, Wei, Xiao, Wenhua, Wei, Rui, Hong, Tianpei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500125/ https://www.ncbi.nlm.nih.gov/pubmed/35963931 http://dx.doi.org/10.1007/s13300-022-01310-3

Ejemplares similares

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
por: Lang, Shan, et al.
Publicado: (2020)

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2015)

Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output
por: Liu, Junling, et al.
Publicado: (2019)

Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2019)

Antagonistic Glucagon Receptor Antibody Promotes α-Cell Proliferation and Increases β-Cell Mass in Diabetic Mice
por: Wei, Rui, et al.
Publicado: (2019)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

An experimental study of exenatide effects on renal injury in diabetic rats
por: Wang, Xiaodong, et al.
Publicado: (2019)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Alleviation of Hyperglycemia Induced Vascular Endothelial Injury by Exenatide Might Be Related to the Reduction of Nitrooxidative Stress
por: Zhao, Qian, et al.
Publicado: (2013)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Exaggerated Liver Injury Induced by Renal Ischemia Reperfusion in Diabetes: Effect of Exenatide
por: Vaghasiya, Jitendra D., et al.
Publicado: (2010)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
por: Raman, Vandana S., et al.
Publicado: (2010)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
por: Kelly, Aaron S, et al.
Publicado: (2012)

Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart
por: Ding, Wei, et al.
Publicado: (2019)

Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study
por: Inaishi, Jun, et al.
Publicado: (2022)

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
por: Garg, Rajesh, et al.
Publicado: (2010)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes
por: Schnabel, Catherine A, et al.
Publicado: (2006)

A review of exenatide as adjunctive therapy in patients with type 2 diabetes
por: Robles, Gisela I, et al.
Publicado: (2009)

Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2014)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud, Aditya, et al.
Publicado: (2015)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022)

Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes
por: Zhang, Yaqin, et al.
Publicado: (2021)

The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study
por: Hu, Yanjin, et al.
Publicado: (2018)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

Exenatide modulates tumor–endothelial cell interactions in human ovarian cancer cells
por: Kosowska, Agnieszka, et al.
Publicado: (2017)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Diabetes, even newly defined by HbA1c testing, is associated with an increased risk of in-hospital death in adults with COVID-19
por: Liu, Ye, et al.
Publicado: (2021)

Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
por: Deng, Wuquan, et al.
Publicado: (2015)

Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial
por: Shi, Xiulin, et al.
Publicado: (2017)

Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
por: Bunck, Mathijs C., et al.
Publicado: (2011)

Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide long‐acting release
por: Takenaka, Kenchi, et al.
Publicado: (2019)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
por: Tatarkiewicz, K, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a2qcmke5kfr0gagkhlifhq9ei4